This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Kazi DS, et al. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial. Annals of Internal Medicine 170: 221-230, No. 4, 19 Feb 2019. Available from: URL: http://dx.doi.org/10.7326/M18-1776
Rights and permissions
About this article
Cite this article
Alirocumab too costly to be cost effective after MI. PharmacoEcon Outcomes News 823, 4 (2019). https://doi.org/10.1007/s40274-019-5694-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5694-z